Cite
Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
MLA
Calfa, Carmen J., et al. “Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.” JCO Precision Oncology, vol. 8, Feb. 2024, pp. 1–13. EBSCOhost, https://doi.org/10.1200/PO.23.00513.
APA
Calfa, C. J., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Ahn, E. R., Burness, M. L., Gogineni, K., Rohatgi, N., Al Baghdadi, T., Conlin, A., Gaba, A., Hamid, O., Krishnamurthy, J., Gavini, N. J., Gold, P. J., Rodon, J., Rueter, J., Thota, R., Grantham, G. N., & Hinshaw, D. C. (2024). Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 8, 1–13. https://doi.org/10.1200/PO.23.00513
Chicago
Calfa, Carmen J., Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Eugene R. Ahn, Monika L. Burness, Keerthi Gogineni, et al. 2024. “Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.” JCO Precision Oncology 8 (February): 1–13. doi:10.1200/PO.23.00513.